Mo Z, Liu M, Yang F, et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer[J]. Breast Cancer Res, 2013, 15(6): R114. [2]Catalano S, Giordano C, Panza S, et al. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth[J]. Breast Cancer Res Treat, 2014, 146(2): 273-285. [3]莫志强, 涂刚, 罗浩军, 等. 人乳腺癌MCF-7他莫昔芬耐药细胞株的建立及鉴定[J]. 第三军医大学学报, 2011, 33(21): 2256-2259. [4]Ward A, Balwierz A, Zhang J D, et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer[J]. Oncogene, 2013, 32(9): 1173-1182. [5]Milani A, Geuna E, Mittica G, et al. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions[J]. World J Clin Oncol, 2014, 5(5):990-1001. [6]Youle R J, Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death[J]. Nat Rev Mol Cell Biol, 2008, 9(1): 47-59. [7]Barclay L A, Wales T E, Garner T P, et al. Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism[J]. Mol Cell, 2015, 57(5): 873-886. [8]Viedma-Rodriguez R, Baiza-Gutman L A, Garcia-Carranca A, et al. Suppression of the death gene BIK is a critical factor for resistance to tamoxifen in MCF-7 breast cancer cells[J]. Int J Oncol, 2013, 43(6): 1777-1786. [9]Dai Y, Grant S. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance[J]. Autophagy, 2015, 11(2): 416-418. [10]Miller A V, Hicks M A, Nakajima W, et al. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor[J]. PLoS One, 2013, 8(4): e60685. [11]Park H K, Lee J E, Lim J, et al. Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim[J]. BMC Cancer, 2014, 14: 431. [12]Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472): 1687-1717. [13]Hackshaw A, Roughton M, Forsyth S, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer[J]. J Clin Oncol, 2011, 29(13): 1657-1663. [14]Sjostrom M, Hartman L, Grabau D, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer[J]. Breast Cancer Res Treat, 2014, 145(1): 61-71. [15]Elbaz M, Nasser M W, Ravi J, et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer[J]. Mol Oncol, 2015, 9(4): 906-919. [16]Kim M R, Choi H K, Cho K B, et al. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells[J]. Cancer Sci, 2009, 100(10): 1834-1841. [17]Lv Y, Song S, Zhang K, et al. CHIP regulates AKT/FoxO/Bim signaling in MCF7 and MCF10A cells[J]. PLoS One, 2013, 8(12): e83312. [18]Periyasamy-Thandavan S, Takhar S, Singer A, et al. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim[J]. Breast Cancer Res, 2012, 14(2): R52.
[2]
付伟杰,杨光伦,涂刚,等.S100p促进乳腺癌MCF-7细胞他莫西芬耐受和细胞迁移[J].第三军医大学学报,2014,36(17):1795. Fu Weijie,Yang Guanglun,Tu Gang,et al.S100p promotes tamoxifen resistance and migration in human breast cancer MCF-7 cells[J].J Third Mil Med Univ,2014,36(22):1795. [2]袁杰,杨丽,陈茂山,等.人乳腺癌MCF-7他莫昔芬耐受细胞株EMT表型的鉴定及其机制的初步研究[J].第三军医大学学报,2014,36(22):2272. Yuan Jie,Yang Li,Chen Maoshan,et al.Identification of epithelial-mesenchymal transition phenotype in tamoxifen-resistant MCF-7 cells[J].J Third Mil Med Univ,2014,36(22):2272.
